Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)

por Bousmah, Marwân-al-Qays, Nishimwe, Marie Libérée, Tovar-Sanchez, Tamara, Lantche Wandji, Martial, Mpoudi-Etame, Mireille, Maradan, Gwenaëlle, Omgba Bassega, Pierrette, Varloteaux, Marie, Montoyo, Alice, Kouanfack, Charles, Delaporte, Eric, Boyer, Sylvie
Publicado 2020

Risks of metabolic syndrome in the ADVANCE and NAMSAL trials

por Tovar Sanchez, Tamara, Mpoudi-Etame, Mireille, Kouanfack, Charles, Delaporte, Eric, Calmy, Alexandra, Venter, Francois, Sokhela, Simiso, Bosch, Bronwyn, Akpomiemie, Godspower, Tembo, Angela, Pepperrell, Toby, Simmons, Bryony, Casas, Carmen Perez, McCann, Kaitlyn, Mirchandani, Manya, Hill, Andrew
Publicado 2023